Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 59Leukemia 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Gastrointestinal Stromal Tumors 12Leukemia, Myeloid, Chronic-Phase 11Neoplasms 5Blast Crisis 4Recurrence 3Bronchiolitis Obliterans Syndrome 3Synovitis, Pigmented Villonodular 2Philadelphia Chromosome 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myeloid 2Hematologic Diseases 2Bone Marrow Diseases 2Sarcoma 1Piebaldism 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplastic Processes 1Myeloproliferative Disorders 1Mucosal Lentiginous Melanoma 1Mastocytosis, Systemic 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 19romidepsin 15fludarabine phosphate 13Whole-Body Irradiation 13Peripheral Blood Stem Cell Transplantation 11Mycophenolic Acid 11Doxorubicin 11Vincristine 10Prednisone 10Cyclosporine 1010-propargyl-10-deazaaminopterin 10Gemcitabine 8Etoposide 8Alemtuzumab 8Bortezomib 6Dexamethasone 5Busulfan 5Brentuximab Vedotin 5mogamulizumab 4denileukin diftitox 4darinaparsin 4Vitamin B 12 4Nivolumab 4Lenalidomide 4Folic Acid 4Carboplatin 4carfilzomib 3belinostat 3Tacrolimus 3Rituximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell, Peripheral × nilotinib × Clear all
NCT01155817 2020-04-15

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Stanford University

Phase 1 Completed
33 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡